The role of RASSF1A methylation in cancer

Disease Markers

Volumn 23, Issue 1-2, 2007, Pages 73-87

  Hesson, Luke B ^a,b   Cooper, Wendy N ^a   Latif, Farida ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

3p21.3; Cancer; Methylation; Ras association domain; RASSF1A; Tumour suppressor gene

Indexed keywords

CISPLATIN; TAMOXIFEN;

BODY FLUID; BREAST CANCER; CANCER DIAGNOSIS; CANCER GENETICS; CANCER RESISTANCE; CPG ISLAND; DISEASE MARKER; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION REGULATION; GENE INACTIVATION; GLIOMA; HUMAN; KIDNEY CANCER; LUNG CANCER; NEUROBLASTOMA; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; RAS ASSOCIATION DOMAIN FAMILY 1 ISOFORM A GENE; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 33847358769     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2007/291538     Document Type: Review

References (138)

1. A. Agathanggelou, I. Bieche, J. Ahmed-Choudhury, B. Nicke, R. Dammann, S. Baksh, B.N. Gao, J.D. Minna, J. Downward, E.R. Maher and F. Latif, Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma, Cancer Res 63 (2003), 5344-5351.
2. A. Agathanggelou, W.N. Cooper and F. Latif, Role of the ras-association domain family 1 tumor suppressor gene in human cancers, Cancer Res 65 (2005), 3497-3508.
3. A. Agathanggelou, S. Honorio, D.P. Macartney, A. Martinez, A. Dallol, J. Radar, P. Fullwood, A. Chauhan, R. Walker, J.A. Shaw, S. Hosoe, M.I. Lerman, J.D. Minna, E.R. Maher and F. Latif, Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours, Oncogene 20 (2001), 1509-1518.
4. K. Akino, M. Toyota, H. Suzuki, H. Mita, Y. Sasaki, M. Ohe-Toyota, J.P.J. Issa, Y. Hinoda, K. Imai and T. Tokino, The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer, Gastroenterology 129 (2005), 156-169.
5. D. Astuti, A. Agathanggelou, S. Honorio, A. Dallol, T. Martinsson, P. Kogner, C. Cummins, H.P.H. Neumann, R. Voutilainen, P. Dahia, C. Eng, E.R. Maher and F. Latif, RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours, Oncogene 20 (2001), 7573-7577.
6. S. Baksh, S. Tommasi, S. Fenton, V.C. Yu, L.M. Martins, G.P. Pfeifer, F. Latif, J. Downward and B.G. Neel, The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to bax conformational change and cell death, Molecular Cell 18 (2005), 637-650.
7. C. Balana, J.L. Ramirez, M. Taron, Y. Roussos, A. Ariza, R. Ballester, C. Sarries, P. Mendez, J.J. Sanchez and R. Rosell, O-6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1- nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme, Clin Cancer Res 9 (2003), 1461-1468.
8. B. Banelli, I. Gelvi, A. Di Vinci, P. Scaruffi, I. Casciano, G. Allemanni, S. Bonassi, G.P. Tonini and M. Romani, Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors, Oncogene 24 (2005), 5619-5628.
9. P.J. Bastian, J. Ellinger, A. Wellmann, N. Wernert, L.C. Heukamp, S.C. Muller and A. von Ruecker, Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci, Clin Cancer Res 11 (2005), 4097-4106.
10. C. Battagli, R.G. Uzzo, E. Dulaimi, I. Ibanez de Caceres, R. Krassenstein, T. Al-Saleem, R.E. Greenberg and P. Cairns, Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients, Cancer Res 63 (2003), 8695-8699.
11. S.A. Belinsky, D.M. Klinge, J.D. Dekker, M.W. Smith, T.J. Bocklage, F.D. Gilliland, R.E. Crowell, D.D. Karp, C.A. Stidley and M.A. Picchi, Gene promoter methylation in plasma and sputum increases with lung cancer risk, Clin Cancer Res 11 (2005), 6505-6511.
12. D.G. Burbee, E. Forgacs, S. Zochbauer-Muller, L. Shivakumar, K. Fong, B.N. Gao, D. Randle, M. Kondo, A. Virmani, S. Bader, Y. Sekido, F. Latif, S. Milchgrub, S. Toyooka, A.F. Gazdar, M.I. Lerman, E. Zabarovsky, M. White and J.D. Minna, Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression, J Natl Cancer Inst 93 (2001), 691-699.
13. D.S. Byun, M.G. Lee, K.S. Chae, B.G. Ryu and S.G. Chi, Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma, Cancer Res 61 (2001), 7034-7038.
14. J.W.F. Catto, A.R. Azzouzi, I. Rehman, K.M. Feeley, S.S. Cross, N. Amira, G. Fromont, M. Sibony, O. Cussenot, M. Meuth and F.C. Hamdy, Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma, J Clin Oncol 23 (2005), 2903-2910.
15. M.W.Y. Chan, L.W. Chan, N.L.S. Tang, K.W. Lo, J.H.M. Tong, A.W.H. Chan, H.Y. Cheung, W.S. Wong, P.S.F. Chan, F.M.M. Lai and K.F. To, Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients, Int J Cancer 104 (2003), 611-616.
16. H.W. Chang, A. Chan, D.L.W. Kwong, W.I. Wei, J.S.T. Sham and A.P.W. Yuen, Evaluation of hypermethylated tumor suppressor genes as tumor markers in mouth and throat rinsing fluid, nasopharyngeal swab and peripheral blood of nasopharygeal carcinoma patient, Int J Cancer 105 (2003), 851-855.
17. J.D. Chen, W.O. Lui, M.D. Vos, G.J. Clark, M. Takahashi, J. Schoumans, S.K. Khoo, D. Petillo, T. Lavery, J. Sugimura, D. Astuti, C. Zhang, S. Kagawa, E.R. Maher, C. Larsson, A.S. Alberts, H.O. Kanayama and B.T. Teh, The t(1;3) breakpoint-spanning involved in clear cell renal cell genes LSAMP and NORE1 are carcinomas, Cancer Cell 4 (2003), 405-413.
18. Y.J. Chen, Q.B. Tang and S.Q. Zou, Inactivation of RASSF1A, the tumor suppressor gene at 3p21.3 in extrahepatic cholangiocarcinoma, World J Gastroenterol 11 (2005), 1333-1338.
19. N. Choi, D.S. Son, I. Song, H.S. Lee, Y.S. Lim, M.S. Song, D.S. Lim, J. Lee, H. Kim and J. Kim, RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer, Int J Cancer 115 (2005), 575-581.
20. L.S. Chow, C.W. Lam, S.Y. Chan, S.W. Tsao, K.F. To, S.F. Tong, W.K. Hung, R. Dammann, D.P. Huang and K.W. Lo, Identification of RASSF1A modulated genes in nasopharyngeal carcinoma, Oncogene (2005), In press.
21. L.S.N. Chow, K.W. Lo, J. Kwong, K.F. To, K.S. Tsang, C.W. Lam, R. Dammann and D.P. Huang, RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma, Int J Cancer 109 (2004), 839-847.
22. L.S.N. Chow, K.W. Lo, J. Kwong, A.Y.H. Wong and D.P. Huang, Aberrant methylation of RASSF4/AD037 in nasopharyngeal carcinoma, Oncol Rep 12 (2004), 781-787.
23. K.W. Choy, T.C. Lee, K.F. Cheung, D.S.P. Fan,K.W. Lo, K.L. Beaverson, D.H. Abramson, D.S.C. Lam, C.B.O. Yu and C.P. Pang, Clinical implications of promoter hypermethylation in RASSF1A and MGMT in retinoblastomal, Neoplasia 7 (2005), 200-206.
24. Y. Cohen, G. Singer, O. Lavie, S.M. Dong, U. Beller and D. Sidransky, The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix, Clin Cancer Res 9 (2003), 2981-2984.
25. A. Dallol, A. Agathanggelou, S.L. Fenton, J. Ahmed-Choudhury, L. Hesson, M.D. Vos, G.J. Clark, J. Downward, E.R. Maher and F. Latif, RASSFIA interacts with microtubule-associated proteins and modulates microtubule dynamics, Cancer Res 64 (2004), 4112-4116.
26. R. Dammann, C. Li, J.H. Yoon, P.L. Chin, S. Bates and G.P. Pfeifer, Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3, Nature Genet 25 (2000), 315-319.
27. R. Dammann, U. Schagdarsurengin, L.M. Liu, N. Otto, O. Gimm, H. Dralle, B. Boehm, G.P. Pfeifer and C. Hoang-Vu, Frequent RASSF1A promoter hypermethylation and Kras mutations in pancreatic carcinoma, Oncogene 22 (2003), 3806-3812.
28. R. Dammann, T. Takahashi and G.P. Pfeifer, The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas, Oncogene 20 (2001), 3563-3567.
29. S.M. Dong, D.I. Sun, N.E. Benoit, I. Kuzmin, M.I. Lerman and D. Sidransky, Epigenetic inactivation of RASSF1A in head and neck cancer, Clin Cancer Res 9 (2003), 3635-3640.
30. K. Dreijerink, E. Braga, I. Kuzmin, L. Geil, F.M. Duh, D. Angeloni, B. Zbar, M.I. Lerman, E.J. Stanbridge, J.D. Minna, A. Protopopov, J.F. Li, V. Kashuba, G. Klein and E.R. Zabarovsky, The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis, Proc Natl Acad Sci USA 98 (2001), 7504-7509.
31. E. Dulaimi, J. Hillinck, I. Ibanez de Caceres, T. Al-Saleem and P. Cairns, Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients, Clin Cancer Res 10 (2004), 6189-6193.
32. E. Dulaimi, I. Ibanez de Caceres, R.G. Uzzo, T. Al-Saleem, R.E. Greenberg, T.J. Polascik, J.S. Babb, W.E. Grizzle and P. Cairns, Promoter hypermethylation profile of kidney cancer, Clin Cancer Res 10 (2004), 3972-3979.
33. E. Dulaimi, R.G. Uzzo, R.E. Greenberg, T. Al-Saleem and P. Cairns, Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel, Clin Cancer Res 10 (2004), 1887-1893.
34. C.A. Eads, K.D. Danenberg, K. Kawakami, L.B. Saltz, C. Blake, D. Shibata, P.V. Danenberg and P.W. Laird, Methy-Light: a high-throughput assay to measure DNA methylation, Nucleic Acids Res 28 (2000), E32.
35. K. Eckfeld, L. Hesson, M.D. Vos, I. Bieche, F. Latif and G.J. Clark, RASSF4/AD037 is a potential ras effector/tumor suppressor of the RASSF family, Cancer Res 64 (2004), 8688-8693.
36. M. Ehrlich, G.C. Jiang, E. Fiala, J.S. Dome, M.C. Yu, T.I. Long, B. Youn, O.S. Sohn, M. Widschwendter, G.E. Tomlinson, M. Chintagumpala, M. Champagne, D. Parham, G.N. Liang, K. Malik and P.W. Laird, Hypomethylation and hypermethylation of DNA in Wilms tumors, Oncogene 21 (2002), 6694-6702.
37. H. Endoh, Y. Yatabe, S. Shmizu, K. Tajima, H. Kuwano, T. Takahashi and T. Mitsudomi, RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication, Int J Cancer 106 (2003), 45-51.
38. M. Endoh, G. Tamura, T. Honda, N. Homma, M. Terashima, S. Nishizuka and T. Motoyama, RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer, Br J Cancer 93 (2005), 1395-1399.
39. L. Fajas, C. Paul, O. Zugasti, L. Le Cam, J. Polanowska, E. Fabbrizio, R. Medema, M.L. Vignais and C. Sardet, pRB binds to and modulates the transrepressing activity of the E1A-regulated transcription factor p120(E4F), Proc Natl Acad Sci USA 97 (2000), 7738-7743.
40. S.L. Fenton, A. Dallol, A. Agathanggelou, L. Hesson, J. Ahmed-Choudhury, S. Baksh, C. Sardet, R. Dammann, J.D. Minna, J. Downward, E.R. Maher and F. Latif, Identification of the E1A-regulated transcription factor p120(E4F) as an interacting partner of the RASSF1A candidate tumor suppressor gene, Cancer Res 64 (2004), 102-107.
41. H. Fiegl, C. Gattringer, A. Widschwendter, A. Schneitter, A. Ramoni, D. Sarlay, I. Gaugg, G. Goebel, H.M. Muller, E. Mueller-Holzner, C. Marth and M. Widschwendter, Methylated DNA collected by tampons - A new tool to detect endometrial cancer, Cancer Epidemiol Biomarkers Prev 13 (2004), 882-888.
42. H. Fiegl, S. Millinger, E. Mueller-Holzner, C. Marth, C. Ensinger, A. Berger, H. Klocker, G. Goebel and M. Widschwendter, Circulating tumor-specific DNA: A marker for monitoring efficacy of adjuvant therapy in cancer patients, Cancer Res 65 (2005), 1141-1145.
43. M.G. Friedrich, D.J. Weisenberger, J.C. Cheng, S. Chandrasoma, K.D. Siegmund, M.L. Gonzalgo, M.I. Toma, H. Huland, C. Yoo, Y.C. Tsai, P.W. Nichols, B.H. Bochner, P.A. Jones and G.N. Liang, Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients, Clin Cancer Res 10 (2004), 7457-7465.
44. O. Galm, S. Wilop, J. Reichelt, E. Jost, G. Gehbauer, J.G. Herman and R. Osieka, DNA methylation changes in multiple myeloma, Leukemia 18 (2004), 1687-1692.
45. D.W. Hamilton, M.E. Lusher, J.C. Lindsey, D.W. Ellison and S.C. Clifford, Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma, Cancer Lett 227 (2005), 75-81.
46. K. Harada, S. Toyooka, A. Maitra, R. Maruyama, K.O. Toyooka, C.F. Timmons, G.E. Tomlinson, D. Mastrangelo, R.J. Hay, J.D. Minna and A.F. Gazdar, Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines, Oncogene 21 (2002), 4345-4349.
47. M. Hasegawa, H.H. Nelson, E. Peters, E. Ringstrom, M. Posner and K.T. Kelsey, Patterns of gene promoter methylation in squamous cell cancer of the head and neck, Oncogene 21 (2002), 4231-4236.
48. J.G. Herman, J.R. Graff, S. Myohanen, B.D. Nelkin and S.B. Baylin, Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands, Proc Natl Acad Sci USA 93 (1996), 9821-9826.
49. L. Hesson, I. Bieche, D. Krex, E. Criniere, K. Hoang-Xuan, E.R. Maher and F. Latif, Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas, Oncogene 23 (2004), 2408-2419.
50. L. Hesson, A. Dallol, J.D. Minna, E.R. Maher and F. Latif, NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers, Oncogene 22 (2003), 947-954.
51. L.B. Hesson, R. Wilson, D. Morton, C. Adams, M. Walker, E.R. Maher and F. Latif, CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations, Oncogene 24 (2005), 3987-3994.
52. R.P. Hogg, S. Honorio, A. Martinez, A. Agathanggelou, A. Dallol, P. Fullwood, R. Weichselbaum, M.J. Kuo, E.R. Maher and F. Latif, Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma, Eur J Cancer 38 (2002), 1585-1592.
53. S. Honorio, A. Agathanggelou, M. Schuermann, W. Pankow, P. Viacava, E.R. Maher and F. Latif, Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients, Oncogene 22 (2003), 147-150.
54. S. Honorio, A. Agathanggelou, N. Wernert, M. Rothe, E.R. Maher and F. Latif, Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours, Oncogene 22 (2003), 461-466.
55. D.S.B. Hoon, M. Spugnardi, C. Kuo, S.K. Huang, D.L. Morton and B. Taback, Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients, Oncogene 23 (2004), 4014-4022.
56. K. Horiguchi, Y. Tomizawa, M. Tosaka, S. Ishiuchi, H. Kurihara, M. Mori and N. Saito, Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors, Oncogene 22 (2003), 7862-7865.
57. I. Ibanez de Caceres, C. Battagli, M. Esteller, J.G. Herman, E. Dulaimi, M.I. Edelson, C. Bergman, H. Ehya, B.L. Eisenberg and P. Cairns, Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients, Cancer Res 64 (2004), 6476-6481.
58. M. Irimia, M.F. Fraga, M. Sanchez-Cespedes and M. Esteller, CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer, Oncogene 23 (2004), 8695-8699.
59. C. Jeronimo, R. Henrique, M.O. Hoque, E. Mambo, F.R. Ribeiro, G. Varzim, J. Oliveira, M.R. Teixeira, C. Lopes and D. Sidransky, A quantitative promoter methylation profile of prostate cancer, Clin Cancer Res 10 (2004), 8472-8478.
60. G.H. Kang, S. Lee, W.H. Kim, H.W. Lee, J.C. Kim, M.G. Rhyu and J.Y. Ro, Epstein-Barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenoty-pepositive gastric carcinoma, Am J Pathol 160 (2002), 787-794.
61. G.H. Kang, S. Lee, H.J. Lee and K.S. Hwang, Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia, J Pathol 202 (2004), 233-240.
62. A. Khokhlatchev, S. Rabizadeh, R. Xavier, M. Nedwidek, T. Chen, X.F. Zhang, B. Seed and J. Avruch, Identification of a novel Ras-regulated proapoptotic pathway, Curr Biol 12 (2002), 253-265.
63. D.H. Kim, J.S. Kim, Y.I. Ji, Y.M. Shim, H. Kim, J.H. Han and J. Park, Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer, Cancer Res 63 (2003), 3743-3746.
64. S. Koul, J. Houldsworth, M.M. Mansukhani, A. Donadio, J.M. McKiernan, V.E. Reuter, G.J. Bosl, R.S. Chaganti and V.V. Murty, Characteristic promoter hypermethylation signatures in male germ cell tumors, Mol Cancer 1 (2002), 8.
65. S. Koul, J.M. McKiernan, G. Narayan, J. Houldsworth, J. Bacik, D.L. Dobrzynski, A.M. Assaad, M. Mansukhani, V.E. Reuter, G.J. Bosl, R.S. Chaganti and V.V. Murty, Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors, Mol Cancer 3 (2004), 16.
66. R. Krassenstein, E. Sauter, E. Dulaimi, C. Battagli, H. Ehya, A. Klein-Szanto and P. Cairns, Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation, Clin Cancer Res 10 (2004), 28-32.
67. T. Kuroki, F. Trapasso, S. Yendamuri, A. Matsuyama, H. Alder, M. Mori and C.M. Croce, Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma, Cancer Res 63 (2003), 3724-3728.
68. I. Kuzmin, J.W. Gillespie, A. Protopopov, L. Geil, K. Dreijerink, Y.F. Yang, C.D. Vocke, F.M. Duh, E. Zabarovsky, J.D. Minna, J.S. Rhim, M.R. Emmert-Buck, W.M. Linehan and M.I. Lerman, The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells, Cancer Res 62 (2002), 3498-3502.
69. I. Kuzmin, L.M. Liu, R. Dammann, L. Geil, E.J. Stanbridge, S.P. Wilczynski, M.I. Lerman and G.P. Pfeifer, Inactivation of RAS association domain family 1A gene in cervical carcinomas and the role of human papillomavirus infection, Cancer Res 63 (2003), 1888-1893.
70. M.G. Lee, H.Y. Kim, D.S. Byun, S.J. Lee, C.H. Lee, J.I. Kim, S.G. Chang and S.G. Chi, Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma, Cancer Res 61 (2001), 6688-6692.
71. S. Lee, K.S. Hwang, H.J. Lee, J.S. Kim and G.H. Kang, Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia, Lab Invest 84 (2004), 884-893.
72. U. Lehmann, F. Langer, H. Feist, S. Glockner, B. Hasemeier and H. Kreipe, Quantitative assessment of promoter hypermethylation during breast cancer development, Am J Pathol 160 (2002), 605-612.
73. S.A. Leon, B. Shapiro, D.M. Sklaroff and M.J. Yaros, Free DNA in Serum of Cancer-Patients and Effect of Therapy, Cancer Res 37 (1977), 646-650.
74. M.I. Lerman and J.D. Minna, for The International Lung Cancer Chromosome 3p21.3 Tumour Suppressor Gene Consortium, The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: Identification and evaluation of the resident candidate tumor suppressor genes, Cancer Res 60 (2000), 6116-6133.
75. C.M. Lewis, L.R. Cler, D.W. Bu, S. Zochbauer-Muller, S. Milchgrub, E.Z. Naftalis, A.M. Leitch, J.D. Minna and D.M. Euhus, Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk, Clin Cancer Res 11 (2005), 166-172.
76. J. Li, A. El-Naggar and L. Mao, Promoter methylation of p16(INK4), RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma, Cancer 104 (2005), 771-776.
77. L.M. Liu, S. Tommasi, D.H. Lee, R. Dammann and G.P. Pfeifer, Control of microtubule stability by the RASSF1A tumor suppressor, Oncogene 22 (2003), 8125-8136.
78. L.M. Liu, J.H. Yoon, R. Dammann and G.P. Pfeifer, Frequent hypermethylation of the RASSF1A gene in prostate cancer, Oncogene 21 (2002), 6835-6840.
79. K.W. Lo, J. Kwong, A.B.Y. Hui, S.Y.Y. Chan, K.F. To, S.C. Chan, L.S.N. Chow, P.M.L.Teo, P.J. Johnson and D.P. Huang, High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma, Cancer Res 61 (2001), 3877-3881.
80. M.E. Lusher, J.C. Lindsey, F. Latif, A.D.J. Pearson, D.W. Ellison and S.C. Clifford, Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development, Cancer Res 62 (2002), 5906-5911.
81. S.I. Maruya, J.P.J. Issa, R.S. Weber, D.I. Rosenthal, J.C. Haviland, R. Lotan and A.K. El-Naggar, Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: Incidence and potential implications, Clin Cancer Res 10 (2004), 3825-3830.
82. R. Maruyama, S. Toyooka, K.O. Toyooka, K. Harada, A.K. Virmani, S. Zochbauer-Muller, A.J. Farinas, F. Vakar-Lopez, J.D. Minna, A. Sagalowsky, B. Czerniak and A.F. Gazdar, Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features, Cancer Res 61 (2001), 8659-8663.
83. R. Maruyama, S. Toyooka, K.O. Toyooka, A.K. Virmani, S. Zochbauer-Muller, A.J. Farinas, J.D. Minna, J. McConnell, E.P. Frenkel and A.F. Gazdar, Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features, Clin Cancer Res 8 (2002), 514-519.
84. J. Mehrotra, M. Vali, M. McVeigh, S.L. Kominsky, M.J. Fackler, J. Lahti-Domenici, K. Polyak, N. Sacchi, E. Garrett-Mayer, P. Argani and S. Sukumar, Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung, Clin Cancer Res 10 (2004), 3104-3109.
85. C. Morrissey, A. Martinez, M. Zatyka, A. Agathanggelou, S. Honorio, D. Astuti, N.V. Morgan, H. Moch, F.M. Richards, T. Kishida, M. Yao, P. Schraml, F. Latif and E.R. Maher, Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma, Cancer Res 61 (2001), 7277-7281.
86. J. Muhlisch, A. Schwering, M. Grotzer, G.H. Vince, W. Roggendorf, C. Hagemann, N. Sorensen, C.H. Rickert, N. Osada, H. Jurgens and M.C. Fruhwald, Epigenetic repression of RASSF1A but not CASP8 in supratentorial PNET (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of childhood, Oncogene (2005), in press.
87. H.M. Muller, A. Widschwendter, H. Fiegl, L. Ivarsson, G. Goebel, E. Perkmann, C. Marth and M. Widschwendter, DNA methylation in serum of breast cancer patients: An independent prognostic marker, Cancer Res 63 (2003), 7641-7645.
88. H.M. Muller and M. Widschwendter, Methylated DNA as a possible screening marker for neoplastic disease in several body fluids, Expert Review of Molecular Diagnostics 3 (2003), 443-458.
89. P.G. Murray, G.H. Qiu, L. Fu, E.R. Waites, G. Srivastava, D. Heys, A. Agathanggelou, F. Latif, R.G. Grundy, J.R. Mann, J. Starczynski, J. Crocker, S.E. Parkes, R.F. Ambinder, L.S. Young and Q. Tao, Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma, Oncogene 23 (2004), 1326-1331.
90. M.H.L. Ng, K.M. Lau, W.S. Wong, K.W. To, S.H. Cheng, K.S. Tsang, N.P.H. Chan, B.C.S. Kho, K.W. Lo, J.H.M. Tong, C.W. Lam and J.C.W. Chan, Alterations of RAS signalling in Chinese multiple myeloma patients: absent BRAF and rare RAS mutations, but frequent inactivation of RASSF1A by transcriptional silencing or expression of a non-functional variant transcript, Br J Haematol 123 (2003), 637-645.
91. K. Okami, A. Sakai, J. Onuki, T. Hamano, M. Iida and M. Takahashi, Promoter hypermethylation of tumor-associated genes in head and neck cancer, Nippon Jibiinkoka Gakkai Kaiho 108 (2005), 207-213.
92. S. Ortiz-Vega, A. Khokhlatchev, M. Nedwidek, X.F. Zhang, R. Dammann, G.P. Pfeifer and J. Avruch, The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1, Oncogene 21 (2002), 1381-1390.
93. Z.G. Pan, V.I. Kashuba, X.Q. Liu, J.Y. Shao, R.H. Zhang, J.H. Jiang, C. Guo, E. Zabarovsky, I. Ernberg and Y.X. Zeng, High Frequency Somatic Mutations in RASSF1A in Nasopharyngeal Carcinoma, Cancer Biol Ther 4 (2005), 1116-1122.
94. M. Praskova, A. Khoklatchev, S. Ortiz-Vega and J. Avruch, Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras, Biochem J 381 (2004), 453-462.
95. Z.R. Qian, T. Sano, K. Yoshimoto, A. Ishizuka, N. Mizusawa, H. Horiguchi, M. Hirokawa and S.L. Asa, Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas, Lab Invest 85 (2005), 464-473.
96. S. Rabizadeh, R.J. Xavier, K. Ishiguro, J. Bernabeortiz, M. Lopez-Ilasaca, A. Khokhlatchev, P. Mollahan, G.P. Pfeifer, J. Avruch and B. Seed, The scaffold protein CNK1 interacts with the tumor suppressor RASSF1A and augments RASSF1A-induced cell death, J Biol Chem 279 (2004), 29247-29254.
97. J.L. Ramirez, M. Taron, C. Balana, C. Sarries, P. Mendez, I. de Aguirre, L. Nunez, B. Roig, C. Queralt, M. Botia and R. Rosell, Serum DNA as a tool for cancer patient management, Rocz Akad Med Bialymst 48 (2003), 34-41.
98. A. Rathi, A.K. Virmani, J.O. Schorge, K.J. Elias, R. Maruyama, J.D. Minna, S.C. Mok, L. Girard, D.A. Fishman and A.F. Gazdar, Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women, Clin Cancer Res 8 (2002), 3324-3331.
99. H. Rizos, E. Diefenbach, P. Badhwar, S. Woodruff, T.M. Becker, R.J. Rooney, and R.F. Kefford, Association of p14(ARF) with the p120(E4F) transcriptional repressor enhances cell cycle inhibition, J Biol Chem 278 (2003), 4981-4989.
100. E.Y. Rykova, P.P. Laktionov, T.E. Skvortsova, A.V. Starikov, N.P. Kuznetsova and V.V. Vlassov, Extracellular DNA in breast cancer - Cell-surface-bound, tumor- derived extracellular DNAin blood of patients with breast cancer and nonmalignant tumors, Annals of the New York Academy of Sciences 1022 (2004), 217-220.
101. P. Sandy, M. Gostissa, V. Fogal, L. De Cecco, K. Szalay, R.J. Rooney, C. Schneider and G. Del Sal, p53 is involved in the p120E4F-mediated growth arrest, Oncogene 19 (2000), 188-199.
102. U. Schagdarsurengin, O. Gimm, C. Hoang-Vu, H. Dralle, G.P. Pfeifer and R. Dammann, Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma, Cancer Res 62 (2002), 3698-3701.
103. V. Schmiemann, A. Bocking, M. Kazimirek, A.S.C. Onofre, H.E. Gabbert, R. Kappes, C.D. Gerharz and H.J. Grote, Methylation assay for the diagnosis of lung cancer on bronchial aspirates: A cohort study, Clin Cancer Res 11 (2005), 7728-7734.
104. S. Seidl, J. Ackermann, H. Kaufmann, A. Keck, T. Nosslinger, C.C. Zielinski, J. Drach and S. Zochbauer-Muller, DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies, Cancer 100 (2004), 2598-2606.
105. L. Shivakumar, J. Minna, T. Sakamaki, R. Pestell and M.A. White, The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation, Mol Cell Biol 22 (2002), 4309-4318.
106. R. Singal, L. Ferdinand, I.M. Reis and J.J. Schlesselman, Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease, Oncol Rep 12 (2004), 631-637.
107. M.S. Song, S.J. Song, N.G. Ayad, J.S. Chang, J.H. Lee, H.K. Hong, H. Lee, N. Choi, J. Kim, H. Kim, J.W. Kim, E.J. Choi, M.W. Kirschner and D.S. Lim, The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex, Nat Cell Biol 6 (2004), 129-137.
108. M. Spugnardi, S. Tommasi, R. Dammann, G.P. Pfeifer and D.S.B. Hoon, Epigenetic inactivation of RAS Association Domain Family Protein 1 (RASSF1A) in malignant cutaneous melanoma, Cancer Res 63 (2003), 1639-1643.
109. K.O. Tan, K.M.L. Tan, S.L. Chan, K.S.Y. Yee, M. Bevort, K.C. Ang and V.C. Yu, MAP-1, a novel proapoptotic protein containing a BH3-like motif that associates with Bax through its Bcl-2 homology domains, J Biol Chem 276 (2001), 2802-2807.
110. K.F. To, W.K. Leung, T.L. Lee, J. Yu, J.H.M. Tong, M.W.Y. Chan, E.K.W. Ng, S.C.S. Chung and J.J.Y. Sung, Promoter hypermethylation of tumor-related genes in gastric intestinal metaplasia of patients with and without gastric cancer, Int J Cancer 102 (2002), 623-628.
111. Y. Tomizawa, T. Kohno, H. Kondo, A. Otsuka, M. Nishioka, T. Niki, T. Yamada, A. Maeshima, K. Yoshimura, R. Saito, J.D. Minna and J. Yokota, Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma, Clin Cancer Res 8 (2002), 2362-2368.
112. O. Topaloglu, M.O. Hoque, Y. Tokumaru, J. Lee, E. Ratovitski, D. Sidransky and C.S. Moon, Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer, Clin Cancer Res 10 (2004), 2284-2288.
113. S. Toyooka, H.I. Pass, N. Shivapurkar, Y. Fukuyama, R. Maruyama, K.O. Toyooka, M. Gilcrease, A. Farinas, J.D. Minna and A.F. Gazdar, Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma, Cancer Res 61 (2001), 5727-5730.
114. S. Toyooka, K.O. Toyooka, R. Maruyama, A.K. Virmani, L. Girard, K. Miyajima, K. Harada, Y. Ariyoshi, T. Takahashi, K. Sugio, E. Brambilla, M. Gilcrease, J.D. Minna and A.F. Gazdar, DNA methylation profiles of lung tumors, Mol Cancer Ther 1 (2001), 61-67.
115. T. Tozawa, G. Tamura, T. Honda, S. Nawata, W. Kimura, N. Makino, S. Kawata, T. Sugai, T. Suto and T. Motoyama, Promoter hypermethylation of DAP-kinase is associated with poor survival in primary biliary tract carcinoma patients, Cancer Sci 95 (2004), 736-740.
116. B.N. Trinh, T.I. Long and P.W. Laird, DNA methylation analysis by MethyLight technology, Methods 25 (2001), 456-462.
117. M. van Engeland, G. Roemen, M. Brink, M.M.M. Paachen, M.P. Weijenberg, A.P. de Bruine, J.W. Arends, P.A. van den Brandt, A. de Goeij and J.G. Herman, K-ras mutations and RASSF1A promoter methylation in colorectal cancer, Oncogene 21 (2002), 3792-3795.
118. D. Vavvas, X. Li, J. Avruch and X.F. Zhang, Identification of Nore1 as a potential Ras effector, J Biol Chem 273 (1998), 5439-5442.
119. M.D. Vos, C.A. Ellis, C. Elam, A.S. Ulku, B.J. Taylor and G.J. Clark, RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor, J Biol Chem 278 (2003), 28045-28051.
120. M.D. Vos, A. Martinez, C. Elam, A. Dallol, B.J. Taylor, F. Latif and G.J. Clark, A role for the RASSF1A tumor suppressor in the regulation of tubulin polymerization and genomic stability, Cancer Res 64 (2004), 4244-4250.
121. M.D. Vos, A. Martinez, C.A. Ellis, T. Vallecorsa and G.J. Clark, The pro-apoptotic Ras effector Nore1 may serve as a Ras- regulated tumor suppressor in the lung, J Biol Chem 278 (2003), 21938-21943.
122. K.J. Wagner, W.N. Cooper, R.G. Grundy, G. Caldwell, C. Jones, R.B. Wadey, D. Morton, P.N. Schofield, W. Reik, F. Latif and E.R. Maher, Frequent RASSF1A tumour suppressor gene promoter methylation in Wilms' tumour and colorectal cancer, Oncogene 21 (2002), 7277-7282.
123. J. Wang, J.J. Lee, L. Wang, D.D. Liu, C. Lu, Y.H. Fan, W.K. Hong and L. Mao, Value of p16(INK4a) and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer, Clin Cancer Res 10 (2004), 6119-6125.
124. M. Widschwendter and P.A. Jones, The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer (Commentary re: J. Kwong et al., Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res, 8: 131-137, 2002, and H.-Z. Zou et al., Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin Cancer Res, 8: 188-191, 2002), Clin Cancer Res 8 (2002), 17-21.
125. P.A. Wingo, L.A.G. Ries, G.A. Giovino, D.S. Miller, H.M. Rosenberg, D.R. Shopland, M.J. Thun and B.K. Edwards, Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking, J Natl Cancer Inst 91 (1999), 675-690.
126. N. Wong, L. Li, K. Tsang, P.B.S. Lai, K.F. To and P.J. Johnson, Frequent loss of chromosome 3p and hypermethylation of RASSF1A in cholangiocarcinoma, J Hepatol 37 (2002), 633-639.
127. T.S. Wong, D.L.W. Kwong, J.S.T. Sham, W.I. Wei, Y.L. Kwong and A.P.W. Yuen, Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma, Clin Cancer Res 10 (2004), 2401-2406.
128. M.Z. Xing, Y. Cohen, E. Mambo, G. Tallini, R. Udelsman, P.W. Ladenson and D. Sidransky, Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis, Cancer Res 64 (2004), 1664-1668.
129. Z.G. Xiong and P.W. Laird, COBRA: A sensitive and quantitative DNA methylation assay, Nucleic Acids Research 25 (1997), 2532-2534.
130. S. Yamaguchi, H. Kato, T. Miyazaki, M. Sohda, H. Kimura, M. Ide, T. Asao and H. Kuwano, RASSF1A gene promoter methylation in esophageal cancer specimens, Diseases of the Esophagus 18 (2005), 253-256.
131. B. Yang, M.G. House, M.Z. Guo, J.G. Herman and D.P. Clark, Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma, Mod Pathol 18 (2005), 412-420.
132. J.H. Yoon, R. Damman and G.P. Pfeifer, Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas, Int J Cancer 94 (2001), 212-217.
133. J. Yu, M. Ni, J. Xu, H.Y. Zhang, B.M. Gao, J.R. Gu, J.G. Chen, L.S. Zhang, M.C. Wu, S.S. Zhen and J.D. Zhu, Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis, BMC Cancer 2 (2002), art. no. 29.
134. M.Y. Yu, J.H.M. Tong, P.K.S. Chan, T.L. Lee, M.W.Y. Chan, A.W.H. Chan,
135. J. Zhang, C.R. Martins, Z.B. Fansler, K.L. Roemer, E.A. Kincaid, K.S. Gustafson, D.F. Heitjan and D.P. Clark, DNA-methylation in anal intraepithelial lesions and anal squamous cell carcinoma, Clin Cancer Res 11 (2005), 6544-6549.
136. Y.J. Zhang, H. Ahsan, Y. Chen, R.M. Lunn, L.Y. Wang, S.Y. Chen, P.H. Lee, C.J. Chen and R.M. Santella, High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B-1-DNA adduct levels in human hepatocellular carcinoma, Mol Carcinog 35 (2002), 85-92.
137. S. Zhong, W. Yeo, M.W. Tang, N. Wong, P.B.S. Lai and P.J. Johnson, Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas, Clin Cancer Res 9 (2003), 3376-3382.
138. S. Zochbauer-Muller, S. Lam, S. Toyooka, A.K. Virmani, K.O. Toyooka, S. Seidl, J.D. Minna and A.F. Gazdar, Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers, Int J Cancer 107 (2003), 612-616.